ADMA BIOLOGICS, INC.
ADMA Biologics is a U.S.-based biopharmaceutical company that manufactures, markets and develops plasma-derived biologics for people with immune deficiencies and others at risk for infectious diseases. Its ADMA BioManufacturing segment produces three FDA-approved, commercially available products: ASCENIV and BIVIGAM, intravenous immune globulins for primary immunodeficiency, and Nabi-HB, a hyperimmune globulin for specified hepatitis B exposures. ADMA also operates a Plasma Collection Centers segment that supplies plasma for manufacturing and sells some collected plasma to third parties. The company manufactures its products at its plasma fractionation and purification facility in Boca Raton, Florida. ADMA makes money from sales of its biologic products and plasma, and also provides contract manufacturing, laboratory, and, as needed, filling, labeling and packing services. Its ADMA BioCenters subsidiary operates plasma collection facilities in the United States. The company is headquartered in Ramsey, New Jersey.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ADMA in the last 30 days.
See all $ADMA insider activity →Adma Biologics (ADMA) reiterated its 2026 revenue target of at least $530M and raised its adjusted EBITDA minimum to $275M, citing accelerating demand for its ASCENIV product. CEO Adam Grossman attributed the growth to commercial momentum. The company reported these updates during its Q3 2026 earnings call.
ADMA BIOLOGICS, INC. (ADMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update 3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Mi
ADMA Biologics published data on its IVIG manufacturing process in Frontiers in Cardiovascular Medicine. The study showed effective impurity removal, maintained immunoglobulin quality, and increased IgG yield. The company specializes in plasma-derived biologics.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning ADMA (ADMA BIOLOGICS, INC.). Coverage has skewed bullish: 6 bullish, 0 neutral, and 0 bearish.
Recent ADMA coverage spans earnings, technology and regulation.
Guidance lift signals stronger sales momentum, likely supporting the stock price.
Guidance raise suggests stronger earnings outlook.
The new IVIG data could improve product safety and margins, potentially boosting ADMA's valuation.
The lawsuit reveals potential revenue inflation and insider sell‑offs, raising fraud risk.
Value‑oriented investors may view ADMA as a bounce‑back opportunity after the sell‑off.
AlphAI scores every news story that mentions ADMA with an AI model for sentiment and relevance, and aggregates insider trades from ADMA BIOLOGICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Adma Biologics (ADMA) reiterated its 2026 revenue target of at least $530M and raised its adjusted EBITDA minimum to $275M, citing accelerating demand for its ASCENIV product. CEO Adam Grossman attributed the growth to commercial momentum. The company reported these updates during its Q3 2026 earnings call.
ADMA BIOLOGICS, INC. (ADMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update 3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Mi
ADMA Biologics published data on its IVIG manufacturing process in Frontiers in Cardiovascular Medicine. The study showed effective impurity removal, maintained immunoglobulin quality, and increased IgG yield. The company specializes in plasma-derived biologics.
ADMA Biologics faces a stockholder lawsuit alleging revenue inflation through channel-stuffing and undisclosed distributor deals. The complaint claims ASCENIV sales were overstated, with distributors holding excess inventory. Insiders allegedly sold shares before a short-seller report caused a 45% stock drop. ADMA denies wrongdoing. The suit seeks recovery for alleged securities violations and breach of fiduciary duty.
Investing.com highlights three mid-cap stocks with low analyst coverage: Rumble (RUM) signed a $13.7B GPU deal, Sellas Life Sciences (SLS) rose 683% in a year, and ADMA Biologics (ADMA) trades at 13.7x earnings after a 44% pullback. RUM's Q2 revenue was $40.4M, up 61% YoY, with Q3 guidance of $87-93M. SLS has a 'Great' health score, while ADMA is profitable and shows early signs of stabilization.
ADMA BIOLOGICS, INC. (ADMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update 2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized wit
The article claims ADMA Biologics received an FDA label expansion for its ASCENIV product, but it provides no additional details or figures. The rest is promotional content for an “Insider Monkey” newsletter, citing broad AI/robotics themes and alleging a prior stock call (British American Tobacco) returned 90% in 16 months.
ADMA Biologics said the FDA approved an expansion of ASCENIV’s label to include pediatric patients aged 2 and older, previously limited to primary humoral immunodeficiency/PI patients aged 12+. The company attributed the change to completion of a required post-marketing pediatric assessment and said it broadens access for younger immune-compromised patients.
Grossman Jerrold B purchased 6,400 shares of ADMA BIOLOGICS, INC. (ADMA) at $7.91 on 2026-05-27.
Jerrold B. Grossman, a director at ADMA Biologics, Inc., recently purchased 12,500 shares of the company's common stock for $100,125, at a price of $8.01 per share. This transaction occurred on May 12, 2026, when the stock was trading near its 52-week low, and follows a recent earnings report where the company missed analyst expectations. Grossman's direct and indirect holdings now total a significant number of shares, indicating his continued investment in the company.
